- Stocks
- Healthcare
- NASDAQ: HBIO

Price (delayed)

$2.79

Market cap

$121.67M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.25

Enterprise value

$158.02M

Harvard Bioscience is a leading developer, manufacturer and seller of technologies, products and services that enable fundamental research, discovery, and pre-clinical testing for drug development. Its customers range from renowned

Harvard Bioscience's debt has decreased by 16% YoY and by 2.3% from the previous quarter

HBIO's gross margin is up by 6% YoY

The company's net income has shrunk by 97% YoY and by 22% QoQ

The EPS has plunged by 92% YoY and by 25% from the previous quarter

Sector: Healthcare

Industry: Medical Instruments & Supplies

Website: http://www.harvardbioscience.com

What are the main financial stats of HBIO

Market
Valuations
Earnings

Shares outstanding

43.61M

Market cap

$121.67M

Enterprise value

$158.02M

Price to earnings (P/E)

N/A

Price to book (P/B)

1.8

Price to sales (P/S)

1.2

EV/EBIT

N/A

EV/EBITDA

178.55

EV/Sales

1.56

Revenue

$101.13M

EBIT

-$6.25M

EBITDA

$885,000

Free cash flow

$5.97M

Per share
Balance sheet
Liquidity

EPS

-$0.25

Free cash flow per share

$0.14

Book value per share

$1.55

Revenue per share

$2.33

TBVPS

$1.35

Total assets

$128.91M

Total liabilities

$61.67M

Debt

$40.39M

Equity

$67.25M

Working capital

$23.81M

Debt to equity

0.6

Current ratio

2.05

Quick ratio

0.73

Net debt/EBITDA

41.07

Margins
Efficiency
Dividend

EBITDA margin

0.9%

Gross margin

58.4%

Net margin

-10.6%

Operating margin

-4.9%

Return on assets

-7.9%

Return on equity

-15.1%

Return on invested capital

-8.3%

Return on capital employed

-5.9%

Return on sales

-6.2%

Dividend yield

N/A

DPS

N/A

Payout ratio

N/A

How has the Harvard Bioscience stock price performed over time

Intraday

-1.41%

1 week

2.2%

1 month

-5.42%

1 year

-33.73%

YTD

-47.85%

QTD

-2.11%

How have Harvard Bioscience's revenue and profit performed over time

Revenue

$101.13M

Gross profit

$59.04M

Operating income

-$5M

Net income

-$10.68M

Gross margin

58.4%

Net margin

-10.6%

HBIO's operating income has dropped by 199% year-on-year and by 134% since the previous quarter

Harvard Bioscience's operating margin has plunged by 145% from the previous quarter

Harvard Bioscience's net margin has plunged by 121% YoY and by 29% from the previous quarter

The company's net income has shrunk by 97% YoY and by 22% QoQ

What is Harvard Bioscience's growth rate over time

What is Harvard Bioscience stock price valuation

P/E

N/A

P/B

1.8

P/S

1.2

EV/EBIT

N/A

EV/EBITDA

178.55

EV/Sales

1.56

The EPS has plunged by 92% YoY and by 25% from the previous quarter

HBIO's price to book (P/B) is 27% less than its last 4 quarters average of 2.5 and 24% less than its 5-year quarterly average of 2.4

The equity has declined by 11% year-on-year and by 2.3% since the previous quarter

The stock's price to sales (P/S) is 28% less than its last 4 quarters average of 1.7 and 24% less than its 5-year quarterly average of 1.6

Harvard Bioscience's revenue has decreased by 11% YoY and by 5% from the previous quarter

How efficient is Harvard Bioscience business performance

HBIO's return on invested capital has dropped by 168% year-on-year and by 36% since the previous quarter

The ROS has plunged by 148% YoY and by 35% from the previous quarter

The return on assets has dropped by 114% year-on-year and by 25% since the previous quarter

The return on equity has dropped by 104% year-on-year and by 26% since the previous quarter

What is HBIO's dividend

DPS

N/A

Dividend yield

N/A

Payout ratio

N/A

There are no recent dividends present for HBIO.

How did Harvard Bioscience financials performed over time

The total assets is 109% more than the total liabilities

HBIO's quick ratio is down by 22% YoY and by 3.9% QoQ

HBIO's current ratio is down by 10% year-on-year but it is up by 9% since the previous quarter

Harvard Bioscience's debt is 40% less than its equity

Harvard Bioscience's debt has decreased by 16% YoY and by 2.3% from the previous quarter

The equity has declined by 11% year-on-year and by 2.3% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified. Data from and Sharadar.